机译:Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent 'value for money' for the NHS? A rapid inquiry into suggestions that it may be cost-effective
Univ Warwick, Fac Sci Engn & Med, Warwick Med Sch, Coventry, W Midlands, England;
Univ Lyon, Sch Pharm ISPB, Pharm Dept, EA P2S, Lyon, France;
Cost-effectiveness; onasemnogene abeparvosec; spinal muscular atrophy; Zolgensma;